

VA/DoD Clinical Practice Guidelines



Management of Pregnancy



Provider Summary

Version 4.0 | 2023



VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF PREGNANCY

Department of Veterans Affairs

Department of Defense

Provider Summary

QUALIFYING STATEMENTS

The Department of Veterans Affairs (VA) and the Department of Defense (DoD) guidelines are based on the best information available at the time of publication. The guidelines are designed to provide information and assist decision making. They are not intended to define a standard of care and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management.

This clinical practice guideline (CPG) is based on a systematic review of both clinical and epidemiological evidence. Developed by a panel of multidisciplinary experts, it provides a clear explanation of the logical relationships between various care options and health outcomes while rating both the quality of the evidence and the strength of the recommendation.

Variations in practice will inevitably and appropriately occur when providers consider the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Therefore, every health care professional using these guidelines is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation with a patient-centered approach.

These guidelines are not intended to represent VA or DoD policies. Further, inclusion of recommendations for specific testing, therapeutic interventions, or both within these guidelines does not guarantee coverage of civilian sector care.

Version 4.0 – July 2023

Table of Contents

Introduction	1
Recommendations	1
Algorithm	4
A. Algorithm Key	4
B. Interventions by Weeks' Gestation	5
Routine Pregnancy Care	9
A. Initial Prenatal Visit.....	9
B. Subsequent Prenatal Visits	18
C. Postpartum	21
D. Education	23
Scope of the CPG	25
Methods	25
Guideline Development Team	26
Patient-centered Care	28
Shared Decision Making	28
References	29

Introduction

The VA and DoD Evidence-Based Practice Work Group (EBPWG) was established and first chartered in 2004, with a mission to advise the VA/DoD Health Executive Committee “on the use of clinical and epidemiological evidence to improve the health of the population . . .” across the Veterans Health Administration (VHA) and Military Health System (MHS), by facilitating the development of CPG for the VA and DoD populations.(1) Development and update of VA/DoD CPGs is funded by VA Evidence Based Practice, Office of Quality and Patient Safety. The system-wide goal of evidence-based CPGs is to improve patient health and wellbeing.

In 2018, VA and DoD published a CPG for the Management of Pregnancy (2018 VA/DoD Pregnancy CPG), which was based on evidence reviewed through May 18, 2017. Since the release of that CPG, the evidence base on pregnancy has expanded. Consequently, the EBPWG initiated the update of the 2018 VA/DoD Pregnancy CPG in 2022. This updated CPG’s use of Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach reflects a more rigorous application of the methodology than previous iterations.(2) Therefore, the strength of some recommendations might have been modified because of the confidence in the quality of the supporting evidence (see [Evidence Quality and Recommendation Strength](#)).

This CPG provides an evidence-based framework for evaluating and managing care for pregnant patients toward improving clinical outcomes. Successful implementation of this CPG will

- Assess the patient’s condition and collaborate with the patient, family, and caregivers to determine optimal management of patient care;
- Emphasize the use of patient-centered care and shared decision making;
- Minimize preventable complications and morbidity; and
- Optimize individual health outcomes and quality of life (QoL).

The full VA/DoD Pregnancy CPG, as well as additional toolkit materials including a Quick Reference Guide and Patient Summary, can be found at:

<https://www.healthquality.va.gov/index.asp>.

Recommendations

The evidence-based clinical practice recommendations listed in [Table 1](#) were developed using a systematic approach considering four domains as per the GRADE approach (see Summary of Guideline Development Methodology in the full text version of the Pregnancy CPG). These domains include confidence in the quality of the evidence, balance of desirable and undesirable outcomes (i.e., benefits and harms), patient values and preferences, and other implications (e.g., resource use, equity, acceptability).

Table 1. Evidence-based Clinical Practice Recommendations with Strength and Category

Topic	Sub-topic	#	Recommendation	Strength ^a	Category ^b
Routine Care	Aneuploidy Screening	1.	We recommend offering non-invasive prenatal testing as the prenatal screening test of choice for all patients with singleton pregnancies who choose aneuploidy screening.	Strong for	Reviewed, New-added
		2.	We suggest non-invasive prenatal testing for patients with twin pregnancies who choose aneuploidy screening.	Weak for	Reviewed, New-added
	Lactation	3.	We suggest assessing all patients for risk factors that impact initiation and continuation of lactation, including obesity, depression, inappropriate gestational weight gain, and gestational diabetes mellitus.	Weak for	Reviewed, New-added
		4.	We suggest individual or group lactation education delivered via in-person, telemedicine, or multimedia modalities be provided for all pregnant and postpartum patients to improve the probability of initiating and continuing lactation.	Weak for	Reviewed, New-replaced
	Pelvic Floor Health	5.	We suggest all patients have an early prenatal evaluation of pelvic floor muscle function and receive pelvic floor muscle exercise instruction during pregnancy for the prevention of urinary incontinence in late pregnancy and up to 6 months postpartum.	Weak for	Reviewed, New-added
		6.	We suggest referral to pelvic health rehabilitation for patients with reported urinary incontinence in the postpartum period.	Weak for	Reviewed, New-added
	Selected Conditions	7.	We recommend offering scheduled delivery to patients who reach 41 weeks and 0/7 days undelivered. Antepartum fetal testing should begin at 41 weeks and 0/7 days if not delivered.	Strong for	Not reviewed, Amended
		8.	We suggest that patients with uncomplicated pregnancies may continue a standard work schedule throughout their pregnancy.	Weak for	Not reviewed, Amended
		9.	We suggest offering telemedicine as a complement to usual perinatal care.	Weak for	Reviewed, New-added
		10.	There is insufficient evidence to recommend for or against specific interventions that would diminish disparities in perinatal care access and maternal and childbirth outcomes.	Neither for nor against	Reviewed, New-added

Topic	Sub-topic	#	Recommendation	Strength ^a	Category ^b
Complicated Obstetrics	Preterm Delivery	11.	We recommend considering fetal fibronectin testing as a part of the evaluation strategy in patients between 24 0/7 and 34 6/7 weeks' gestation with signs and symptoms of preterm labor, particularly in facilities where the result might affect management of delivery.	Strong for	Not reviewed, Amended
		12.	We suggest vaginal progesterone or cerclage for singleton pregnancy with short cervix, history of spontaneous preterm birth, or both depending on patient characteristics and preferences.	Weak for	Reviewed, New-added
		13.	There is insufficient evidence to recommend for or against the use of aspirin to reduce recurrent spontaneous preterm birth.	Neither for nor against	Reviewed, New-added
	Hypertensive Disorders	14.	We recommend initiating aspirin therapy at or before 16 weeks' gestation in patients at risk of developing preeclampsia.	Strong for	Reviewed, New-replaced
		15.	We suggest low-dose aspirin of 100–150 mg daily for patients at risk of preeclampsia.	Weak for	Reviewed, New-replaced
		16.	We suggest patients with cardiometabolic disorders (e.g., gestational diabetes mellitus, hypertension, and obesity) be counseled on the benefits of following the Dietary Approaches to Stop Hypertension diet.	Weak for	Reviewed, New-added
		17.	There is insufficient evidence to recommend for or against self-monitoring for blood pressure during pregnancy and the postpartum period.	Neither for nor against	Reviewed, New-added
	Bariatric Surgery	18.	We suggest patients who have undergone bariatric surgery be evaluated for nutritional deficiencies and the need for nutritional supplementation where indicated (e.g., vitamin B12, folate, iron, calcium).	Weak for	Not reviewed, Amended
		19.	There is insufficient evidence to recommend for or against the routine supplementation of vitamins A, D, E, or K for pregnant patients who have undergone bariatric surgery.	Neither for nor against	Not reviewed, Amended
Mental Health	Screening	20.	We recommend screening for use of tobacco and nicotine products, alcohol, cannabis, illicit drugs, and inappropriate use of prescription medication. See VA/DoD Substance Use Disorders CPG.	Strong for	Not reviewed, Amended
		21.	We recommend screening for depression periodically using a standardized tool, such as the Edinburgh Postnatal Depression Scale or the 9-item Patient Health Questionnaire, during pregnancy and postpartum.	Strong for	Not reviewed, Not changed
		22.	We suggest screening patients with posttraumatic stress disorder (PTSD) for active PTSD and offering PTSD treatment. See VA/DoD PTSD CPG.	Weak for	Reviewed, New-added

Topic	Sub-topic	#	Recommendation	Strength ^a	Category ^b
Mental Health (cont.)	Treatment	23.	We recommend offering individual or group Interpersonal Psychotherapy or cognitive behavioral therapy for pregnant patients at risk of perinatal depression.	Strong for	Reviewed, New-added
		24.	We recommend offering Interpersonal Psychotherapy for treating depression during pregnancy or postpartum.	Strong for	Reviewed, New-added
		25.	We suggest offering cognitive behavioral therapy for treating depression during pregnancy or postpartum.	Weak for	Reviewed, New-added
		26.	We suggest offering peer support for people with perinatal depression or risk of perinatal depression to improve depressive symptoms.	Weak for	Reviewed, New-added
		27.	We suggest exercise, mindfulness, yoga, or any combination of these interventions for depressive symptoms in perinatal patients.	Weak for	Reviewed, New-added
		28.	We suggest offering psychotherapies (e.g., cognitive behavioral therapy, Interpersonal Psychotherapy) or yoga or both for anxiety symptoms during and after pregnancy.	Weak for	Reviewed, New-added

^a Additional information is available in the full CPG: see Determining Recommendation Strength and Direction.

^b Additional information is available in the full CPG: see Recommendation Categorization.

Algorithm

This algorithm is designed to inform providers of the recommended interventions and appropriate timing of each of the recommended interventions for pregnant patients during pregnancy and in the postpartum period. The interventions included in the algorithm are paired with the corresponding recommendation in the VA/DoD Clinical Practice Guideline for the Management of Pregnancy. Following the algorithm, the narrative sections in the full text CPG and the Routine Pregnancy Care section in the full text CPG provide additional information.

A. Algorithm Key

[Table 2](#) displays the key to the algorithm symbols and their meanings.

Table 2. Algorithm Key

Symbol	Meaning
P	Action to be carried out by obstetric provider
R	Referral to be made to an advanced prenatal care provider (e.g., obstetrician, maternal-fetal medicine physician) or other allied health professional
L	Lab or labs to be ordered
Dotted	Pregnant patient to receive this action at this time (Timing is not ideal, but it is still helpful for the patient rather than not at all.)
V1	First visit
PP	Postpartum visit

Interventions	Weeks' Gestation																																									PP									
	First Trimester							Second Trimester														Third Trimester																													
	V1	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41																
Screen for Rh status, anemia, and hemoglobinopathies.	L																																																		
Evaluate for nutritional deficiencies in patients who have undergone bariatric surgery. See Recommendations 18 and 19 in the full CPG.	P																																																		
Refer patients who have undergone bariatric surgery or are on a restrictive diet to an RDN. See Table 13 in the full CPG.	R																																																		
Perform dating ultrasound. See <i>Early (Dating) Ultrasound</i> in the full CPG.				P																																															
Perform pelvic muscle function evaluation and provide training on pelvic muscle exercises during pregnancy. See Recommendation 5 in the full CPG.				P																																															
Offer group model of prenatal care. See <i>Group Prenatal Care</i> in the full CPG.				P																																															
Offer prenatal screening for aneuploidy with NIPT and common genetic disorders. See Recommendation 1 in the full CPG.							P																																												
Offer prenatal diagnostic testing for aneuploidy as an accepted alternative to screening.							P																																												
Initiate low-dose aspirin therapy for patients at risk for preeclampsia. See Recommendations 14 and 15 in the full CPG.							P																																												
Offer MSAFP screening for open spine defects to pregnant patients who did not have serum aneuploidy screening or who had NIPT.																																																			
Offer antenatal progesterone therapy in consultation with an advanced prenatal care provider for patients at high risk for recurrent spontaneous preterm delivery. See Recommendation 12 in the full CPG.																																																			
Complete fetal anatomy ultrasound. See <i>Anatomy (Dating) Ultrasound</i> in the full CPG.																																																			

Routine Pregnancy Care

This CPG does not address every aspect of routine pregnancy care and is not intended to be a comprehensive guide to all care needed in pregnancy. In some cases, clinically important and part of the generally accepted standard of pregnancy care interventions do not have sufficient high-quality evidence to support a standalone recommendation. Additionally, some recommendations included in past versions of this CPG were determined by the Work Group to consistently be supported by the evidence to warrant inclusion as accepted standards of care without needing further evidence review. Lastly, the scope of the Work Group was limited to selected priority topics based on the needs of pregnant patients served by the VA and DoD health systems, which precluded review of all potentially relevant aspects of pregnancy care. The below information can be used to help guide providers during the routine aspects of the management of pregnancy.

A. Initial Prenatal Visit

a. Routine Lab Screening

The following panel of labs is recommended for all patients at the beginning of pregnancy to be done in conjunction with the initial prenatal visit. There are also optional labs that should be offered to all patients and some selective labs performed in response to the presence of certain risk factors. [Table 4](#) lists the three types of prenatal lab panels.

Table 4. Prenatal Lab Panels

Prenatal Lab Panels		
Recommended for All Patients	<ul style="list-style-type: none"> • Blood type • Antibody screen • Complete blood count • Rubella status • Varicella status • Hepatitis B surface antigen 	<ul style="list-style-type: none"> • Hepatitis C antibody • HIV status • Syphilis screen • Urine culture • Gonorrhea screen • Chlamydia screen
Offered to All Patients	<ul style="list-style-type: none"> • Hemoglobin electrophoresis • Aneuploidy screening • Cystic fibrosis carrier screening 	<ul style="list-style-type: none"> • Spinal muscle atrophy carrier screening • Maternal serum alpha fetoprotein (15-22 weeks)
Selective Labs	<ul style="list-style-type: none"> • Cervical cytology, with or without HPV DNA • Comprehensive metabolic panel • Urine spot protein/creatinine ratio • 1-hour 50 gm oral glucose challenge test • Hemoglobin A1C • Thyroid stimulating hormone test 	<ul style="list-style-type: none"> • If due for screening or surveillance • At risk for developing preeclampsia • At risk for developing preeclampsia • Increased risk for GDM • Pregestational diabetes mellitus • Pregestational diabetes mellitus, thyroid disease

Prenatal Lab Panels		
Selective Labs (cont.)	<ul style="list-style-type: none"> • Free thyroxine test • Fragile X screening 	<ul style="list-style-type: none"> • Thyroid disease • Family history of related disorder, or suggestive intellectual disability

Abbreviations: GDM: gestational diabetes mellitus; HIV: human immunodeficiency virus; HPV: human papillomavirus

b. Early (Dating) Ultrasound

Accurate dating is crucial to the management of pregnancy because it drives the milestones and decision making for the application of appropriate monitoring and intervention as the pregnancy proceeds. The estimated due date is initially established by calculating 280 days from the first day of the last normal menstrual period. This practice has the potential to produce an inaccurate due date because only about 50% of patients accurately recall the date of the last menstrual period or because menstrual cycles might be shorter or longer than 28 days or might be irregular.⁽³⁾ The Work Group advises a first-trimester ultrasound to establish or confirm the gestational age and estimated birth date and to confirm the presence of cardiac activity. For pregnant patients who present after the first trimester, we advise performing a dating and anatomical ultrasound at the earliest opportunity, preferably before 22 weeks. Besides confirming or establishing an estimated due date, there are other indications for performing an ultrasound early in pregnancy, including evaluation of vaginal bleeding, confirmation of an intrauterine location, presence and chronicity of multiple gestations, presence of uterine anomalies, or presence of other pelvic pathology. Patients with complaints of bleeding or pain should be referred for immediate ultrasound on presentation.

c. Genetic Screening

The many different methods for screening for fetal aneuploidy are offered at different times during a pregnancy. Although considered optional, prenatal fetal aneuploidy screening and diagnostic testing should be offered to all pregnant patients, regardless of risk of aneuploidy. Offering prenatal screening and diagnostic testing for aneuploidy, regardless of maternal age or risk factors, respects the values and preferences of patients who make this choice. See Recommendations 1 and 2 in the full CPG for further information on screening recommendations.

In addition to tests that screen for aneuploidy, maternal serum alpha-fetoprotein (MSAFP) can be used to screen for neural tube defects (NTD) such as open spina bifida. When performed between 15 and 22 weeks, this test is not a part of NIPT (prenatal cell-free DNA screening [cfDNA]) and should, therefore, be offered to patients who choose to undergo NIPT for their aneuploidy screening test. That MSAFP might have limited use on its own as a screening test is important to note given studies suggesting high-quality ultrasound has a higher detection rate for NTDs.⁽⁴⁾ However, unexplained elevated MSAFP (elevated MSAFP unrelated to a diagnosis of open NTD or other anatomic malformation) is associated with an increased risk of adverse outcomes, such as preterm birth, preterm rupture of membranes (ROM), preeclampsia, fetal growth restriction,

abnormal placentation, and intrauterine fetal death.^(5, 6) Therefore, we advise that pregnant patients with an unexplained elevation of MSAFP be evaluated and counseled by an advanced prenatal care qualified obstetric provider because of the increased risk for adverse perinatal outcomes. If cfDNA testing is chosen for aneuploidy screening, and MSAFP testing is desired, providers should *not* order serum screening (e.g., quad screen) with MSAFP because additional aneuploidy screening increases the risk of false positives and inconsistent lab results with no additional benefit.

In contrast to aneuploidy screening and MSAFP, genetic testing (e.g., parental carrier testing) can be done before or during pregnancy without need to repeat in a future pregnancy. These genetic tests include hemoglobin electrophoresis (to screen for hemoglobinopathy), carrier screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA), which should be offered to all patients. In addition, fragile X carrier screening should be offered to patients at increased risk of the condition based on personal or family history of fragile X–related disorders (e.g., premature ovarian insufficiency, elevated follicle stimulating hormone level before age 40, a known FMR1 premutation, family history of intellectual disability suggestive of fragile X syndrome). A more comprehensive carrier screen panel may be considered for patients of Ashkenazi Jewish ancestry.⁽⁷⁾

d. Infectious Disease Screening

Screening for infectious diseases, listed below, during pregnancy per current guidance from the CDC is recommended. Appropriate follow-up treatment, prophylaxis treatment, or both depending on the history, known exposure, and symptoms of infectious disease are necessary.

- Gonorrhea
- Chlamydia
- Syphilis
- Human immunodeficiency virus (HIV)
- Hepatitis B virus
- Hepatitis C virus
- Rubella
- Varicella
- Human papillomavirus (HPV) (if the patient has a history of an abnormal cervical screen)
- Herpes simplex virus (HSV)
- Asymptomatic bacteriuria
- Tuberculosis
- Group B streptococcus (GBS)

Infectious diseases during pregnancy can cause significant morbidity and mortality in both the pregnant patient and the fetus. According to the CDC, screening for infectious diseases, counseling, and treatment can improve maternal and fetal outcomes.⁽⁸⁾

Group B streptococcus infections are the leading cause of serious neonatal infections (e.g., sepsis, meningitis, pneumonia) within the first 7 days of life (early-onset infection). Antenatal screening is recommended for all pregnant patients between 36 0/7–37 6/7

weeks, except for patients already identified as candidates for GBS prophylaxis based on urine culture or history of a prior affected infant. Because new exposures and infectious agents can emerge (e.g., Zika, COVID, monkeypox), referring to the most recent CDC guidance is important. Screening can lead to diagnosis in asymptomatic persons and can allow pregnant patients an opportunity to be treated.

e. Obstetric Risk Factor Assessment

Many conditions can adversely impact the outcome of a pregnancy, potentially placing the patient and fetus at risk for complications. Although this resource is not intended to provide guidance on the management of high-risk pregnancies, it does identify conditions that should be managed in consultation with an advanced prenatal care provider, as detailed in Tables 10.1–10.3 in the full CPG. As part of the initial evaluation, the primary obstetric provider must assess for certain risk factors early in the pregnancy because interventions, monitoring, and education throughout the pregnancy can have a positive impact on outcomes.

f. Preeclampsia

Given that preeclampsia is one of the leading causes of maternal morbidity and mortality, early identification of patients at risk for developing it is important. As detailed in Recommendations 14 and 15 in the full CPG, patients at high risk for developing preeclampsia should be treated with low-dose aspirin therapy to reduce that risk. An early evaluation might also consist of a complete metabolic panel and urine protein/creatinine ratio in patients at risk for having underlying hepatic or renal disease. [Table 5](#) delineates risk factors associated with developing preeclampsia. Patients with one or more high-risk factors or two or more moderate-risk factors should be offered low-dose aspirin therapy between 12 and 28 weeks’ gestation (optimally before 16 weeks) and should be continued daily until delivery.

Table 5. Clinical Risk Factors for Preeclampsia⁽⁹⁾

High Risk Factors	Moderate Risk Factors
<ul style="list-style-type: none"> • History of preeclampsia • Multifetal gestation • Chronic hypertension • Pregestational Type 1 or 2 diabetes mellitus • Renal disease • Autoimmune disease (e.g., antiphospholipid syndrome, systemic lupus erythematosus) 	<ul style="list-style-type: none"> • Nulliparity • Obesity (body mass index >30) • Family history of preeclampsia • Black persons (due to social, rather than biological, factor^a) • Lower income • Age 35 years or older • In vitro conception • Personal risk factors^b

^a These factors are associated with increased risk due to environmental, social, and historical inequities shaping health exposures, access to health care, and the unequal distribution of resources, not biological propensities.

^b Low birth weight, previous adverse pregnancy outcomes, >10 years since last pregnancy.

g. Diabetes Mellitus

With increasing rates of both pregestational diabetes mellitus and GDM in the pregnant population in the U.S., providers might encounter patients who potentially benefit from early identification of GDM or new diagnoses of pregestational diabetes mellitus made in early pregnancy. Gestational diabetes mellitus affects about 4% of all pregnancies, and risk factors include having a prior pregnancy affected by GDM; having a prior delivery of a baby weighing more than 9 pounds at birth; being overweight or obese; having a family history of DM; being African American, Hispanic, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander; being treated for HIV.⁽¹⁰⁾ The Work Group did attempt to specifically examine the evidence on the utility of early GDM screening to reduce the incidence of gestational hypertension (GHTN), preeclampsia, or GDM. With this focused, narrow prompting question, only one pragmatic RCT met review criteria, which randomized 922 obese patients with a BMI greater than 30 to either early screening (14–20 weeks) or treatment as usual (TAU) (GDM screening at 24–28 weeks).⁽¹¹⁾ The results showed a potentially associated increased risk for GHTN and preeclampsia in the early GDM screening group, but the confidence intervals around the effect estimates for each of the three outcomes were wide and crossed 1.0, such that the differences between early care and TAU screening groups did not reach statistical significance. Future research is needed to define more clearly the benefits and harms of early GDM screening, optimal diagnostic thresholds and testing strategies for early screening, and potentially the patients who benefit most.

When considering early GDM screening for patients with multiple risk factors for GDM, providers should use clinical judgment regarding the benefits and harms of offering such early screening depending on individual patient characteristics. The Work Group also notes that American College of Obstetricians and Gynecologists (ACOG) and the United States Preventative Services Task Force (USPSTF) both offer guidance on early GDM screening for patients with multiple risk factors to support provider decision making regarding early GDM screening for patients with risk factors.^(12, 13)

h. Spontaneous Preterm Birth

Affecting nearly 1 in 10 newborns, preterm birth is a major cause of perinatal morbidity and mortality. One-half of preterm births are related to spontaneous preterm labor. Although many risk factors are associated with spontaneous preterm birth, the strongest predictor is the history of spontaneous preterm birth. Other strong risk factors include prior preterm pre-labor ROM, multiple gestation, and short cervix. Given the time-sensitive nature to implement preventive strategies, the primary obstetric provider should assess the patient's risk for preterm birth at the initial prenatal visit. Patients at high risk for subsequent spontaneous preterm delivery should be counseled on the options for prevention. Women experiencing psychological distress related to high-risk status of having a spontaneous preterm birth or because of a history of spontaneous preterm birth should be offered mental health treatment. See Recommendation 12 in the full CPG for further information.

i. Screening for Intimate Partner Violence

Women who have served in the military are at higher risk of experiencing IPV than those who have never served in the military.⁽¹⁴⁾ Women who experience IPV have a higher likelihood of unintended pregnancies and shorter interpregnancy intervals, in part because of reproductive coercion and reduced access to contraception.⁽¹⁵⁻¹⁸⁾ Experiencing IPV during pregnancy is associated with reduced prenatal care and increased use of addictive substances.^(19, 20) Independent of those factors, experiencing IPV while pregnant is associated with an increased risk of preterm birth, low birth weight, perinatal loss, and death by homicide or suicide.⁽²¹⁻²³⁾

Perinatal care providers are especially well positioned to screen for IPV because of the frequency of health care contacts and opportunities for privacy.⁽²⁴⁾ It is important to screen more than once because individuals might feel unready to disclose initially. Several IPV screening tools have been validated, including the Modified E-HITS (Extended Hurt – Insult – Threaten – Scream), which has been validated for use with women Veterans.^(25, 26) For patients who screen positive for IPV, we recommend completing an assessment and providing information, intervention, referrals, or any combination of these supports, as needed.

j. Depression Screening

Screening pregnant and postpartum patients for depression using a validated screening tool is more effective than usual clinical assessment in detecting depression and in reducing depressive symptoms, particularly when performed with access to interventions such as treatment protocols, care management, and trained providers.⁽²⁷⁾ Providers should screen patients at the first presentation, week 28 of gestation, and at the postpartum visit.

The Edinburg Postnatal Depression Scale (EPDS) and the Patient Health Questionnaire-9 (PHQ-9) are among the screening tools validated for perinatal use. Both screening tools are readily available in VA and DoD clinical settings. See Recommendation 21 in the full CPG for further information.

k. Substance Use Assessment

Perinatal use of alcohol, cigarettes, cannabis, illicit drugs, or unauthorized use of prescription medication is common and might be associated with adverse effects. Screening for use of these substances should occur at each prenatal and postpartum visit followed by additional evaluation and treatment based on screening results. See [Recommendation 20](#) for further information.

l. Immunization Assessment

All pregnant and breastfeeding patients should be immunized according to current CDC schedules for vaccination. Immunizations of the birthing patient decrease the risk of life- or fetus-threatening diseases during pregnancy. Pregnant people are relatively

immunocompromised and can be severely affected by influenza, COVID-19, and other infectious pathogens. Immunizations help protect the birthing patient from infection. They also enhance the passive immunity of infants to pathogens that cause life-threatening illnesses.(28) Pertussis and influenza vaccines are recommended to be given during each pregnancy. Some patients might have concerns about the safety of vaccination in pregnancy; therefore, providers should be well versed in the safety and benefits of vaccine administration. In addition, providers should discuss with patients the immunization recommendations for the baby’s family members and caregivers as provided by the CDC.(29)

Although the following list represents recommended vaccines to receive as a part of routine prenatal and postpartum care, active duty Service members are required to obtain many more vaccines for mission readiness. That pregnant Service members consult with their perinatal care provider is important to determine which vaccines are safe to take during pregnancy and which ones should be delayed until the postpartum period.

1. Given during Pregnancy

- **Pertussis:** Also known as whooping cough, pertussis is a highly contagious bacterial disease that can cause coughing and difficulty breathing. Pertussis poses a significant burden on infants and can be very serious or deadly, especially in those younger than 1 year. Pertussis-related hospitalizations and deaths are highest in infants younger than 2 months.(28) People who are pregnant should receive the Tdap (tetanus, diphtheria, and pertussis) vaccine during each pregnancy to provide passive immunity to infants, who would not otherwise routinely receive it until 2 months of age.(30) Although a pregnant person can receive the Tdap vaccine at any time during pregnancy, the optimal time to receive the vaccine is from 27–36 weeks’ gestation, maximizing maternal antibody response and passive antibody transfer to the newborn. People who do not receive the Tdap vaccine during pregnancy should receive it in the immediate postpartum period if they had never received a prior dose. People who did not receive the Tdap vaccine during pregnancy but had received a prior dose of Tdap in their lifetime should not receive Tdap postpartum.(31)
- **Influenza:** Patients who acquire influenza during pregnancy are at increased risk for spontaneous abortion, maternal morbidity, and even death.(32) For this reason, all people who are or will be pregnant during influenza season should receive the influenza vaccine (an inactivated virus). According to the CDC, influenza vaccination is safe for both the pregnant patient and the fetus, regardless of gestational age. Influenza immunization has also been proven to protect both the birthing parent and child from influenza for several months after birth.(33)
- **COVID-19:** Pregnant and recently pregnant patients are more likely to develop severe illness from COVID-19 compared with people who are not pregnant. The CDC recommends COVID-19 vaccination and staying up-to-date with boosters

for everyone age 6 months and older, including pregnant and lactating patients.(34) COVID-19 infection during pregnancy is associated with an increased likelihood of adverse pregnancy outcomes including preterm birth and stillbirth.(35) Accumulating evidence supports the safety and effectiveness of COVID-19 vaccination during pregnancy. No increased risk of miscarriage, stillbirth, or birth defects have been identified with mRNA COVID-19 administration. No safety concerns were observed in animal studies. COVID-19 vaccination has been shown to reduce the risk of severe illness because of COVID-19 during pregnancy when comparing vaccinated versus nonvaccinated populations. Preliminary data suggest that there might be passive immunity and protection of infants, but more study is needed.(28)

2. Given Following Pregnancy

- **Varicella:** People with varicella infection during pregnancy have a 10–20% risk of developing pneumonia, a significant risk factor for maternal mortality, which is estimated to be as high as 40%.(36) In pregnancy, varicella might cross the placenta, resulting in congenital or neonatal varicella infection. Infection during the first half of pregnancy has been associated with congenital varicella syndrome.(37) Neonatal varicella zoster virus (VZV) infection is associated with a high neonatal death rate.(38) If the pregnant patient is determined to be not-immune by titers or other screening method (e.g., history of vaccination or disease), vaccination is recommended during the postpartum period. The vaccine is contraindicated during pregnancy. According to the CDC, patients who get the varicella vaccine may continue to breastfeed.(39-41)
- **Rubella:** Infection in the first 16 weeks of pregnancy can cause miscarriage or congenital rubella syndrome.(42) Because of concerns about possible teratogenicity and the theoretical risk to the fetus in administering a live vaccine to a pregnant patient, the measles, mumps, and rubella (MMR) vaccination is not recommended during pregnancy.(43, 44) Patients who are not immune to rubella should be vaccinated postpartum. According to the CDC, MMR vaccine is safe to receive during breastfeeding.(45)
- **Human papillomavirus:** The HPV vaccine is not recommended during pregnancy. It is not known to cause harm in a pregnant patient or fetus, but no specific studies evaluating the safety in the pregnant population exist. Vaccination should be delayed until after pregnancy. The vaccine may be administered to patients who are lactating.(46)

m. Medication and Supplement Review

Taking medicines during pregnancy is common; about 9 in 10 women take at least one medicine during pregnancy, and 7 in 10 take at least one prescription medication.(47) Medication review and reconciliation should occur at every prenatal visit and should include screening for potentially teratogenic medications, newly prescribed medications

since the last prenatal visit, over-the-counter medications, supplements, vitamins, and dietary or herbal products. The CDC has partnered with other federal agencies and non-federal partners to improve the health of pregnant people and fetuses by working to identify the safest treatment options for the management of common conditions before and during pregnancy.⁽⁴⁸⁾ As potentially teratogenic medications are identified, we recommend referral to a maternal-fetal medicine specialist.

n. Pelvic Muscle Function

A brief pelvic floor muscle evaluation should be conducted early in pregnancy, using a single-digit palpation to assess pelvic muscle strength, with follow-up instructions on how to properly facilitate an appropriate muscle contraction without compensatory patterns (e.g., gluteal or adductor muscle activation). If a patient is unable to activate their pelvic floor musculature, referral to a pelvic health rehabilitation specialist for PFMT would be appropriate. See Table 11 in the full CPG and Recommendation 5 and Recommendation 6 in the full CPG for further details.

A pelvic floor muscle activation exercise involves a muscle contraction and upward/inward movement of at least the following muscles: levator ani, obturator internus, transverse perineal, bulbocavernosus, ischiocavernosus, and anal sphincters.⁽⁴⁹⁾ Adjacent supporting muscle groups include the adductors, gluteals, and abdominal wall musculature commonly activated using compensatory strategies when pelvic floor muscle weakness or mobility limitations exist. The quality of the pelvic muscle contraction can be documented with the Laycock Pelvic Floor Manual Muscle Test Scale, which uses a 6-point Oxford scale (0=no contraction, 1=flicker, 2=weak, 3=moderate, 4=good [with lift], and 5=strong) during the internal examination to measure pelvic floor muscle strength in women.^(50, 51) Defined as repeated voluntary muscle contractions, PFMT can be conducted independently or with supervision by trained providers as part of a comprehensive exercise program during pregnancy. Provider feedback training on proper pelvic floor muscle activation is critical before prescribing PFMT to patients.

Providers should also screen and adhere to trauma-informed care concepts while considering a patient's receptivity to pelvic examinations. Rates of sexual trauma are known to be high in military female Veterans and Service members.^{(52) (53)} The recommended examination and training can be conducted easily in a short amount of time during an early pregnancy visit concurrent with a cervical cancer screening or ultrasound examination. If the patient is unable to appropriately activate the pelvic floor musculature or has a significant weakness, referral to a pelvic health rehabilitation specialist for further evaluation and treatment would be suitable (Table 11 in the full CPG).

B. Subsequent Prenatal Visits

a. Actions at Every Visit

The frequency of obstetric visits should be individualized. Typically, a patient with an uncomplicated first pregnancy is examined every 4 weeks until 28 weeks' gestation, every 2 weeks from 28–36 weeks' gestation, and then every week until delivery. People with medical or obstetric complications might require closer surveillance, and parous people without medical or obstetric complications, who have had prior normal pregnancy outcomes, may be seen less frequently as long as additional appointments are available as needed.[\(54\)](#)

Certain actions should be completed consistently at every visit, but other actions will be more specific to the gestational age.

During each regularly scheduled visit, the obstetric provider should evaluate the blood pressure, patient weight, uterine size for progressive growth and consistency with gestational age, and presence of fetal heart activity at appropriate gestational ages. After the pregnant patient reports quickening and at each prenatal visit thereafter, the obstetric provider should ask about fetal movement.[\(54\)](#)

b. Blood Pressure

Routinely measuring blood pressure at every visit is important in the early detection and continued management of HDP.[\(54, 55\)](#) Hypertensive disorders of pregnancy are associated with severe maternal complications, including myocardial infarction (MI) and stroke, and are a leading cause of pregnancy-related death in the U.S.[\(56\)](#) Early identification of HDP through blood pressure measurement can reduce morbidity, mortality, and severe complications, including death, through timely intervention and treatment.

c. Weight Gain

Routinely measuring weight for pregnant patients at every visit is useful in monitoring appropriate weight gain and allows the provider to offer interventions that can improve the short-term and long-term health of a pregnant patient and their fetus. Patients who are overweight or obese are at greater risk for adverse health conditions during the preconception, antepartum, and postpartum periods. Patients with low body mass index (BMI) are also at risk for adverse maternal and neonatal outcomes. Inadequate weight gain is a risk factor for spontaneous abortion, preterm birth, fetal growth restriction, HDP, and poor perinatal outcomes. Patients with anorexia nervosa might be identified by a low initial BMI, inadequate antepartum weight gain, or both.[\(57\)](#) This screening is particularly important in the military and Veteran population because studies have suggested that this population might be at greater risk for BMI-associated obstetrical complications.[\(58\)](#) More information regarding recommended weight gain is shown in [Table 6](#).

Table 6. Weight Gain Recommendations for Singletons and Twins⁽⁵⁹⁾

Pre-pregnancy Weight (BMI in kg/m ²)	Singletons	Twins
Underweight (BMI <18.5)	12.7–18.2 kgs (28–40 lbs)	22.7–28.1 kgs (50–62 lbs)
Normal Weight (BMI 18.5–24.9)	11.3–15.9 kgs (25–35 lbs)	16.8–24.5 kgs (37–54 lbs)
Overweight (BMI 25.0–29.9)	6.8–11.3 kgs (15–25 lbs)	14.1–22.7 kgs (31–50 lbs)
Obese (BMI ≥30.0)	5.0–9.1 kgs (11–20 lbs)	11.3–19.1 kgs (25–42 lbs)

Abbreviations: BMI: body mass index; kg/m²: kilograms per square meter; kgs: kilograms; lbs: pounds

d. Fundal Assessment, Fetal Heart Tones, Fetal Movement

Assessment of the fundal height at each visit, beginning at 20 weeks' gestation, is a simple, inexpensive test to monitor expected growth. Fetal heart tones are recommended at each antenatal visit to confirm a viable fetus and to provide psychological reassurance to the pregnant patient. The pregnant patient's perception of fetal movements is the oldest and most commonly used method to assess fetal wellbeing as decreased fetal movement has been associated with an increased risk of stillbirth.⁽⁶⁰⁾

e. Anatomy (Dating) Ultrasound

An integral part of routine antenatal care, antenatal ultrasonography is widely used in pregnancy to assess fetal growth and anatomy and to detect fetal anomalies. It is recommended as an accurate method of determining gestational age, fetal number, viability, anatomic survey, placental location, amniotic fluid, and assessment of pelvic organs. The optimal timing of the complete fetal anatomy ultrasound is in the second trimester between 18 and 22 weeks' gestation. Ultrasonography should be performed by technologists or providers who have undergone specific training and only when a valid medical indication for examination is present.

The diagnosis of a fetal anomaly significantly reduces perinatal mortality and morbidity and maternal morbidity. Prenatal diagnosis enables a psychologically less traumatic and early medical termination of pregnancy for patients who choose abortion. It also enables planning for specific fetal palliative care for patients who elect to continue pregnancy. It decreases probable complications of continuation of pregnancy and labor, prevents an unnecessary cesarean section for a fetus with lethal anomalies diagnosed too late for medical termination of pregnancy, allows planning delivery at the optimal time in a well-equipped tertiary care center with necessary neonatal care facilities, and allows in utero therapy in selected cases. Based on evidence currently available, routine clinical scanning of every pregnant patient using real-time B-mode (2-D) imaging is not contraindicated.

The standard ultrasound evaluation includes the evaluation of fetal presentation, amniotic fluid volume, fetal cardiac activity, placental position, fetal biometry, and fetal number plus an anatomic survey.

f. 24–28 Weeks

1. Family Planning

The ideal time to begin an in-depth discussion with the patient with respect to family planning goals is 24–28 weeks' gestation. Formulating these goals at this point better prepares the patient for an optimal individualized plan in the event of a preterm delivery or if immediate postpartum contraception is desired. See the [Education](#) section for additional details on family planning.

2. Gestational Diabetes Mellitus

Screening for GDM using the 1-hour 50 gram oral glucose challenge (GCT) test is recommended for all pregnant patients beginning at 24 weeks of pregnancy.(61) Screening is ideally completed by 28 weeks of pregnancy. Patients who screen positive should undergo a 3-hour 100 gram oral glucose tolerance test to establish a diagnosis. See the section on [Diabetes Mellitus](#) which discusses the potential role of GDM screening before 24–28 weeks. Should a diagnosis of GDM be established during the pregnancy, maternity care providers should take care to perform a 2-hour 75 gram oral glucose tolerance test at the 6–8 weeks postpartum visit to ensure resolution of the GDM. Given the increased lifetime risk for progression to type 2 DM, communication of this pregnancy complication to subsequent primary care providers is important and affects subsequent lifetime DM screening recommendations.

3. Complete Blood Count – Anemia

Because of plasma volume expansion and increased iron requirements during pregnancy, all pregnant patients should be rescreened for anemia between 24–28 weeks of pregnancy.(62) In the second trimester, hemoglobin and hematocrit values below 10.5 and 32.0, respectively, warrant further investigation and treatment. Values below 11.0 and 33.0 in the third trimester require additional investigation and treatment.

4. Tdap

Pregnant patients should receive the Tdap vaccine during each pregnancy to provide passive immunity through breastmilk to newborns, who would not otherwise routinely receive it until 2 months of age.(30) Although a pregnant patient can receive the Tdap vaccine at any time during pregnancy, the optimal time to receive the vaccine is from 27–36 weeks' gestation, maximizing maternal antibody response and passive antibody transfer to the newborn.

5. Rho(D) Immune Globulin

Rhogam for the prevention of Rh(D) alloimmunization should be given to all Rh-negative pregnant patients at the 28-weeks prenatal visit.

“The USPSTF recommends repeated Rh(D) antibody testing for all unsensitized Rh(D)-negative women at 24 to 28 weeks' gestation unless the biological father is known to be Rh(D)-negative.”(63)

6. Depression Screening

Pregnant patients should be screened for depression using validated instruments (e.g., EPDS, PHQ-9) at approximately 28 weeks. See [Recommendation 21](#) for further details.

g. 36 Weeks

1. Group B Streptococcus Screening

Group B streptococcus is the leading cause of early-onset sepsis in newborns, the primary risk factor being maternal colonization of the genitourinary and gastrointestinal tracts. Antenatal screening is recommended for all pregnant patients between 36 0/7–37 6/7 weeks, except for patients already identified as candidates for GBS prophylaxis based on urine culture or history of a prior affected infant.[\(64\)](#) A single vaginal and rectal swab should be used to collect the sample for culture, and antibiotics should be initiated in labor for patients who screen positive.[\(65\)](#) Samples collected by a provider or patient self-collected are acceptable methods of screening.[\(66\)](#) GBS culture is highly predictive of colonization within 5 weeks of collection; repeat screening should be considered if more than 5 weeks have elapsed before the onset of labor.[\(64\)](#)

2. Fetal Presentation

Assessment of fetal presentation should take place at 36 weeks' gestation, ideally, with the use of ultrasound for confirmation.[\(67, 68\)](#) Cephalic presentation will be found in many patients; in the case of non-cephalic presentation, counseling and intervention are recommended. If a breech presentation is found, an external cephalic version (ECV) should be offered at 37 weeks if there is no contraindication.[\(69\)](#) This timing allows adequate opportunity for spontaneous cephalic version, minimizes the chance of reversion if successful, and reduces the chance of iatrogenic preterm delivery. Potential benefits of this management include improving vaginal delivery rates and reducing the morbidity associated with cesarean delivery. ECV can be offered to patients with or without a previous cesarean birth.[\(70\)](#)

C. Postpartum

To optimize the current and future health of recently pregnant patients and their neonates, postpartum care should be treated as an ongoing process, instead of a single encounter. The care should be tailored to the patient's individual needs.[\(71\)](#)

Ideally, all patients should have initial contact with their obstetric provider within 3 weeks of birth; this initial assessment can be done either in-person or via telehealth. By the end of this visit, a plan for individualized postpartum follow-up care should be determined.

Prioritizing early in-person follow-up rather than telehealth alone should be considered for individuals with a high risk of postpartum depression, high risk of cesarean wound infection or perineal wound infection (from third- or fourth-degree lacerations), lactation difficulties, or chronic conditions likely to require postpartum medication titration.

All individuals with HDP should be assessed no later than 7–10 days after delivery. Individuals with severe HTN should additionally have a blood pressure evaluation within 72 hours of hospital discharge after birth.

All patients should have a comprehensive postpartum visit with their obstetric provider no later than 12 weeks after birth. The timing of this visit should be individualized, and patient centered and should take into account insurance coverage for postpartum care but usually occurs 6–12 weeks following birth. The comprehensive postpartum visit should include an interval history and assessment of physical wellbeing as well as screening and assessment of mood and social wellbeing factors, infant care and feeding, sexual function, contraception, birth spacing, sleep and fatigue, physical recovery from birth, pelvic floor disorders, chronic disease management, and health maintenance.

Individuals with uncomplicated medical histories, deliveries, and postpartum courses will generally transition to ongoing routine care with their primary care provider following the comprehensive postpartum visit with their obstetric provider. This ongoing follow-up and adequate transition from obstetric care to primary care is important for all patients, but it is especially important for individuals who experienced complications during pregnancy and in the postpartum period. Hypertensive disorders of pregnancy, preterm delivery, and GDM are associated with a higher lifetime risk of maternal cardiometabolic disease and warrant additional counseling. Hypertensive disorders, DM, thyroid disorders, renal disease, mood disorders, obesity, substance use disorders, and complex social determinants of health needs warrant communication from the obstetric care provider to the primary care provider and team to coordinate ongoing and long-term follow-up care. Within the VA system, MCCs—patient navigators specifically designated to work with pregnant patients and coordinate their care—contact patients postpartum and assess for medical complications of pregnancy as well as ongoing medical, behavioral, and social determinants of health needs. Based on this assessment, the MCC makes appropriate referrals including mental health, social work, and primary care follow-up, highlighting key issues to the primary care team.

a. Postpartum Contraception

Contraceptive counseling should be initiated during prenatal care, and a plan should be made for postpartum contraception before delivery. Patients should be counseled on all available contraceptive options tailored to the patient’s preference and medical history. Counseling should include immediate postpartum long-acting reversible contraceptives (LARC).⁽⁷²⁾ Immediate postpartum LARC, for people who desire them, may support these patients to receive their preferred contraceptive while avoiding the logistical complexity of attending an in-person visit during the first weeks postpartum. Removing these barriers for patients at high risk of future medical complications in future pregnancies might be particularly beneficial.⁽⁷³⁾

Contraception should be addressed with all patients during their postpartum visits to make any needed adjustments to the postpartum contraceptive care plan.⁽⁷²⁾

D. Education

a. Breastfeeding/Chestfeeding

Current guidelines endorsed by multiple medical organizations recommend exclusive breastfeeding/chestfeeding for 6 months and continued breastfeeding/chestfeeding for up to 2 years or beyond with the addition of complementary foods per the desires and goals of the parent or parents. Birthing parent benefits of breastfeeding/chestfeeding include positive impacts on a person's risk of breast cancer, ovarian cancer, hypertensive heart disease, and DM. Child benefits include reduced risk of otitis media, SIDS, childhood leukemia, obesity, and many other acute and chronic disorders.(74, 75) Even with these known benefits and recommendations, more than one-half of women in the U.S. stop breastfeeding earlier than they desire.(76) Breastfeeding rates of Service members are lower than the national average in the U.S. general population by 7% at 6 months (51%) and 10% at 12 months (25%).(77) We advise health care providers to incorporate mechanisms and processes within their practice to enable people to achieve their infant feeding goals, including patient education throughout pregnancy, access to lactation specialists, community support, and active mitigation of potential barriers. See Recommendation 3 and Recommendation 4 in the full CPG for further information.

b. Oral Health

Pregnancy presents a unique opportunity for health care professionals to positively impact the oral health of patients. Occurring in up to 40% of pregnant people, periodontal disease is associated with adverse perinatal outcomes, including preterm delivery, low birth weight, fetal growth restriction, and preeclampsia.(78, 79) Although recommendations for treatment of periodontal disease cannot be endorsed specifically at this time to decrease these outcomes, evidence indicates that treatment is safe and is associated with the improvement in maternal oral health.(78-80) Pregnancy is not a significant contraindication to most dental services, though some procedures requiring general anesthesia might be deferred to the postpartum period. Oral health care is not just a component of a healthy pregnancy; evidence suggests that most infants and young children acquire caries-causing bacteria from their mothers.(81) Routine dental care, including x-rays (with proper anatomic shielding) and periodontal therapy, along with good oral hygiene, should be encouraged throughout pregnancy.(81, 82)

c. Family Planning and Contraception

Assessment of future reproductive goals during the prenatal period is important to allow for adequate education and planning for the implementation of desired contraceptive therapies during the postpartum period. Providers should counsel patients on the recommendations for interpregnancy intervals to optimize their overall health and reduce the risk of adverse perinatal outcomes in subsequent pregnancies.(83) Given that 70% of pregnancies occurring within 1 year after delivery are unintended, access to and initiation of reliable forms of contraception to include emergency contraception during the postpartum period are essential to ensure women meet their reproductive

and family-planning goals.(84) These measures include access to the immediate postpartum placement of LARCs and postpartum sterilization, where appropriate, because these methods are associated with lower rates of unintended pregnancies in active duty Service members.(85) Contraceptive education and counseling should be an integral part of routine prenatal care to optimize the provision of contraceptive and family-planning services during the postpartum and interpregnancy periods.

d. Exercise and Work

The U.S. Department of Health and Human Services recommends that pregnant patients engage in at least 150 minutes of moderate-intensity aerobic activity each week during pregnancy and postpartum barring no complications that would prevent otherwise.(86) Benefits of exercising during pregnancy include an increased chance for a vaginal delivery and reductions in weight gain, GDM, gestational HDP, preterm birth, low birth rate, and cesarean birth.(87) We recommend that all healthy, pregnant patients without known contraindications participate in regular mild to moderate exercise sessions, three or more times per week. We suggest that patients be provided with education on the safety and benefits of maintaining appropriate levels of activity and exercise during the pregnancy and postpartum period. We also suggest that patients with uncomplicated pregnancies may continue a standard work schedule throughout their pregnancy. See Recommendation 8 in the full CPG for more details. Patients should be instructed to conduct pelvic floor muscle exercises during and after pregnancy to improve function and reduce the risk of developing urinary incontinence during and after pregnancy. See Recommendation 5 in the full CPG for more details.

e. Vitamins

We suggest a daily multivitamin that includes at least 400 micrograms of folic acid be taken starting 1 month before conception and continued throughout pregnancy and lactation. People in the U.S. commonly supplement their diet with vitamins and minerals during pregnancy. Supplementation with multivitamins and minerals has also been associated with improved outcomes, including lower risks of preeclampsia and three forms of childhood cancer (pediatric brain tumors, neuroblastomas, and leukemia).(88, 89) Studies have found that preconception folic acid supplements, either alone or combined with other vitamins or minerals (e.g., in a multivitamin), reduce the risk of NTDs and should be continued through the first trimester of pregnancy.(90-92) Higher doses of folic acid are recommended in certain patients at high risk for NTDs (e.g., patients with a history of an NTD-affected pregnancy).

f. Group Prenatal Care

A group model of prenatal care can be an acceptable alternative to individual provider appointments. Evidence exists that group prenatal care is associated with lower rates of preterm delivery, especially among African-American women.(93-95) Also, no evidence of harm through participation in group prenatal care has been found. Given that patient preferences and values might affect a patient's desire to pursue individualized care

versus group care, offering group prenatal care would allow patients to choose how they engage in health care and could potentially lead to increased patient satisfaction in their care. It also might allow for more efficient use of resources to include low-density specialists who can offer preventive education and support (e.g., pelvic health rehabilitation providers, registered dietician nutritionists [RDN], lactation consultants). Patients should be educated on these potential benefits and offered a group model option of prenatal care, where available, as an acceptable alternative to individual appointments.

Scope of the CPG

This CPG is based on published clinical evidence and related information available through June 1, 2022. It is intended to provide general guidance on best evidence-based practices (see Appendix A in the full text CPG for additional information on the evidence review methodology). Although the CPG is intended to improve the quality of care and clinical outcomes (see [Introduction](#)), it is not intended to define a standard of care (i.e., mandated or strictly required care).

The patient population of interest for this CPG is pregnant patients who are eligible for care in the VA or DoD health care delivery systems, and those who receive care from community-based providers. It includes Veterans and Service members as well as their dependents.

This CPG is intended for use by VA and DoD providers and other providers involved in the care of pregnant patients. Additionally, this CPG is intended for community-based providers involved in the care of pregnant Service members, beneficiaries, or Veterans.

Methods

The Work Group used the GRADE approach to craft each recommendation and determine its strength. Per the GRADE approach, recommendations must be evidence based and cannot be made based on expert opinion alone. The GRADE approach uses the following four domains to inform the strength of each recommendation (see Determining Recommendation Strength and Direction).[\(96\)](#)

1. Confidence in the quality of the evidence
2. Balance of desirable and undesirable outcomes
3. Patient values and preferences
4. Other considerations, as appropriate (e.g., resource use, equity, acceptability, feasibility, subgroup considerations)

Using these four domains, the Work Group determined the relative strength of each recommendation (*Strong* or *Weak*). The strength of a recommendation is defined as the extent to which one can be confident that the desirable effects of an intervention outweigh its undesirable effects and is based on the framework above, which incorporates the four

domains.⁽⁹⁷⁾ A *Strong* recommendation generally indicates *High* or *Moderate* confidence in the quality of the available evidence, a clear difference in magnitude between the benefits and harms of an intervention, similar patient values and preferences, and understood influence of other implications (e.g., resource use, feasibility).

In some instances, insufficient evidence exists on which to base a recommendation for or against a particular therapy, preventive measure, or other intervention. For example, the systematic evidence review might have found little or no relevant evidence, inconclusive evidence, or conflicting evidence for the intervention. The manner in which this finding is expressed in the CPG might vary. In such instances, the Work Group might include among its set of recommendations a statement of insufficient evidence for an intervention that might be in common practice although it is unsupported by clinical evidence and particularly if other risks of continuing its use might exist (e.g., high opportunity cost, misallocation of resources). In other cases, the Work Group might decide to exclude this type of statement about an intervention. For example, the Work Group might remain silent where an absence of evidence occurs for a rarely used intervention. In other cases, an intervention might have a favorable balance of benefits and harms but might be a standard of care for which no recent evidence has been generated.

Using these elements, the Work Group determines the strength and direction of each recommendation and formulates the recommendation with the general corresponding text, as shown in [Table 7](#).

Table 7. Strength and Direction of Recommendations and General Corresponding Text

Recommendation Strength and Direction	General Corresponding Text
Strong for	We recommend . . .
Weak for	We suggest . . .
Neither for nor against	There is insufficient evidence to recommend for or against . . .
Weak against	We suggest against . . .
Strong against	We recommend against . . .

Guideline Development Team

Table 8. Guideline Work Group and Guideline Development Team

Organization	Names*
Department of Veterans Affairs	Carrie Kairys, DNP, FNP-BC (Champion)
	Elizabeth W. Patton, MD, MPhil, MSc, FACOG (Champion)
	Alicia Christy, MD, MHSCR
	Sophia Hill-Smith, MSN, RN
	Ashley Lauria, MA, RD, LDN, IBCLC

Organization	Names*
Department of Veterans Affairs (cont.)	Lisa Longo, PharmD, BCPS
	Laura Miller, MD
	Lauren Pachi, LCSW, CLC
	Tammy Tenace, BSN, MS, ARNP-BC
Department of Defense	Michael Clark, MD, FACOG (Champion)
	Dalia Wenckus, MD, FACOG (Champion)
	Colleen C. Blosser, MSN, RN
	Michael Bybel, DO, FAAFP
	Christine Higgins, DNP
	Adam Edward Lang, PharmD
	Leigh Anne Lechanski, PT, DPT, OCS
	Amanda Owens, DO, FACOG
	Kristi Shearer, PhD
VA Evidence Based Practice, Office of Quality and Patient Safety Veterans Health Administration	James Sall, PhD, FNP-BC
	Jennifer Ballard-Hernandez, DNP, RN, FNP-BC
	René Sutton, BS, HCA
	Eric Rodgers, PhD, FNP-BC
Clinical Quality Improvement Program Defense Health Agency	Elaine P. Stuffel, MHA, BSN, RN
	Cynthia F. Villarreal, BSN, RN
	Isabella M. Alvarez, MA, BSN, RN
The Lewin Group	Clifford Goodman, PhD
	Jennifer Weil, PhD
	Erika Beam, MS
	Savannah Kucera, MPH, RN
	Amanda Heinzerling, MS
	Kristen Godwin, MPH
	Andrea Dressel, BS
ECRI	Stacey Uhl, MS
	Kelley Tipton, MPH
	Laura Koepfler, MLS
Sigma Health Consulting	Frances M. Murphy, MD, MPH
	James Smirniotopoulos, MD
Duty First Consulting	Kate Johnson, BS
	Rachel Piccolino, BA
	Anita Ramanathan, BA

* Additional contributor contact information is available in Appendix E (in the full VA/DoD Pregnancy CPG).

Patient-centered Care

Intended to consider patient needs and preferences, guideline recommendations represent a whole/holistic health approach to care that is patient centered, culturally appropriate, and available to people with limited literacy skills and physical, sensory, or learning disabilities. VA/DoD CPGs encourage providers to use a patient-centered, whole/holistic health approach (i.e., individualized treatment based on patient needs, characteristics, and preferences). This approach aims to treat the particular condition while also optimizing the individual's overall health and wellbeing.

Regardless of the care setting, all patients should have access to individualized evidence-based care. Patient-centered care can decrease patient anxiety, increase trust in providers, and improve treatment adherence.^(98, 99) A whole/holistic health approach (<https://www.va.gov/wholehealth/>) empowers and equips individuals to meet their personal health and wellbeing goals. Good communication is essential and should be supported by evidence-based information tailored to each patient's needs. An empathetic and non-judgmental approach facilitates discussions sensitive to gender, culture, ethnicity, and other differences.

Shared Decision Making

This CPG encourages providers to practice shared decision making, a process in which providers, patients, and patient care partners (e.g., family, friends, caregivers) consider clinical evidence of benefits and risks as well as patient values and preferences to make decisions regarding the patient's treatment.⁽¹⁰⁰⁾ Shared decision making is emphasized in *Crossing the Quality Chasm*, an Institute of Medicine, now NAM, report in 2001⁽¹⁰¹⁾ and is inherent within the whole/holistic health approach. Providers must be adept at presenting information to their patients regarding individual treatments, expected risks, expected outcomes, and levels or settings of care or both, especially where patient heterogeneity in weighing risks and benefits might exist. VHA and MHS have embraced shared decision making. Providers are encouraged to use shared decision making to individualize treatment goals and plans based on patient capabilities, needs, and preferences.

References

1. U.S. Department of Veterans Affairs/Department of Defense Health Executive Committee (HEC). Evidence Based Practice Work Group Charter [updated January 9, 2017]. Available from: www.healthquality.va.gov/documents/EvidenceBasedPracticeWGCharter123020161.pdf.
2. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol*. 2011;64(4):395-400. Epub 2011/01/05. doi: 10.1016/j.jclinepi.2010.09.012. PubMed PMID: 21194891.
3. Wegienka G, Baird DD. A comparison of recalled date of last menstrual period with prospectively recorded dates. *J Womens Health (Larchmt)*. 2005;14(3):248-52. Epub 2005/04/29. doi: 10.1089/jwh.2005.14.248. PubMed PMID: 15857271.
4. Norem CT, Schoen EJ, Walton DL, Krieger RC, O'Keefe J, To TT, et al. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. *Obstet Gynecol*. 2005;106(4):747-52. Epub 2005/10/04. doi: 10.1097/01.AOG.0000178780.63956.3b. PubMed PMID: 16199631.
5. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, et al. Quad screen as a predictor of adverse pregnancy outcome. *Obstet Gynecol*. 2005;106(2):260-7. Epub 2005/08/02. doi: 10.1097/01.AOG.0000172419.37410.eb. PubMed PMID: 16055573.
6. Summers AM, Langlois S, Wyatt P, Douglas Wilson R. RETIRED: Prenatal screening for fetal aneuploidy. *J Obstet Gynaecol Can*. 2007;29(2):146-61. Epub 2007/03/10. doi: 10.1016/s1701-2163(16)32379-9. PubMed PMID: 17346485.
7. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. *Obstet Gynecol*. 2017;129(3):e41-e55. Epub 2017/02/23. doi: 10.1097/aog.0000000000001952. PubMed PMID: 28225426.
8. Centers for Disease Control and Prevention. Pregnancy [updated September 27, 2022]. Available from: <https://www.cdc.gov/pregnancy/index.html>.
9. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. *Jama*. 2021;326(12):1186-91. Epub 2021/09/29. doi: 10.1001/jama.2021.14781. PubMed PMID: 34581729.
10. National Diabetes Education Program. National Diabetes Education Program - Gestational diabetes: Centers for Disease Control and Prevention. Available from: <https://www.cdc.gov/diabetes/diabetesatwork/pdfs/gestationaldiabetes.pdf>.
11. Harper LM, Jauk V, Longo S, Biggio JR, Szychowski JM, Tita AT. Early gestational diabetes screening in obese women: a randomized controlled trial. *Am J Obstet Gynecol*. 2020;222(5):495.e1-.e8. Epub 2020/01/09. doi: 10.1016/j.ajog.2019.12.021. PubMed PMID: 31926951.
12. Force UPST. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;326(6):531-8. doi: 10.1001/jama.2021.11922.
13. ACOG Practice Bulletin Number 190: Gestational diabetes mellitus. ACOG. 2018.

14. Dichter ME, Wagner C, True G. Timing of Intimate Partner Violence in Relationship to Military Service Among Women Veterans. *Mil Med*. 2015;180(11):1124-7. Epub 2015/11/06. doi: 10.7205/milmed-d-14-00582. PubMed PMID: 26540701.
15. Samankasikorn W, Alhusen J, Yan G, Schminkey DL, Bullock L. Relationships of Reproductive Coercion and Intimate Partner Violence to Unintended Pregnancy. *J Obstet Gynecol Neonatal Nurs*. 2019;48(1):50-8. Epub 2018/11/06. doi: 10.1016/j.jogn.2018.09.009. PubMed PMID: 30391221.
16. Maxwell L, Nandi A, Benedetti A, Devries K, Wagman J, García-Moreno C. Intimate partner violence and pregnancy spacing: results from a meta-analysis of individual participant time-to-event data from 29 low-and-middle-income countries. *BMJ Glob Health*. 2018;3(1):e000304. Epub 2018/03/23. doi: 10.1136/bmjgh-2017-000304. PubMed PMID: 29564152.
17. Rosenfeld EA, Miller E, Zhao X, Sileanu FE, Mor MK, Borrero S. Male partner reproductive coercion among women veterans. *Am J Obstet Gynecol*. 2018;218(2):239.e1-.e8. Epub 2017/10/24. doi: 10.1016/j.ajog.2017.10.015. PubMed PMID: 29056537.
18. Kusunoki Y, Barber JS, Gatny HH, Melendez R. Physical Intimate Partner Violence and Contraceptive Behaviors Among Young Women. *J Womens Health (Larchmt)*. 2018;27(8):1016-25. Epub 2017/09/29. doi: 10.1089/jwh.2016.6246. PubMed PMID: 28956704.
19. Musa A, Chojenta C, Geleto A, Loxton D. The associations between intimate partner violence and maternal health care service utilization: a systematic review and meta-analysis. *BMC Womens Health*. 2019;19(1):36. Epub 2019/02/28. doi: 10.1186/s12905-019-0735-0. PubMed PMID: 30808353.
20. Creech SK, Pulverman CS, Kroll-Desrosiers A, Kinney R, Dichter ME, Mattocks K. Intimate Partner Violence Among Pregnant Veterans: Prevalence, Associated Mental Health Conditions, and Health Care Utilization. *J Gen Intern Med*. 2021;36(10):2982-8. Epub 2021/01/20. doi: 10.1007/s11606-020-06498-3. PubMed PMID: 33464464.
21. Berhanie E, Gebregziabher D, Berihu H, Gerezgiher A, Kidane G. Intimate partner violence during pregnancy and adverse birth outcomes: a case-control study. *Reprod Health*. 2019;16(1):22. Epub 2019/02/26. doi: 10.1186/s12978-019-0670-4. PubMed PMID: 30803448.
22. Pastor-Moreno G, Ruiz-Pérez I, Henares-Montiel J, Petrova D. Intimate partner violence during pregnancy and risk of fetal and neonatal death: a meta-analysis with socioeconomic context indicators. *Am J Obstet Gynecol*. 2020;222(2):123-33.e5. Epub 2019/08/09. doi: 10.1016/j.ajog.2019.07.045. PubMed PMID: 31394067.
23. Campbell J, Matoff-Stepp S, Velez ML, Cox HH, Laughon K. Pregnancy-Associated Deaths from Homicide, Suicide, and Drug Overdose: Review of Research and the Intersection with Intimate Partner Violence. *J Womens Health (Larchmt)*. 2021;30(2):236-44. Epub 2020/12/10. doi: 10.1089/jwh.2020.8875. PubMed PMID: 33295844.
24. ACOG Committee Opinion No. 518: Intimate partner violence. *Obstet Gynecol*. 2012;119(2 Pt 1):412-7. Epub 2012/01/25. doi: 10.1097/AOG.0b013e318249ff74. PubMed PMID: 22270317.

25. Deshpande NA, Lewis-O'Connor A. Screening for intimate partner violence during pregnancy. *Rev Obstet Gynecol*. 2013;6(3-4):141-8. Epub 2013/01/01. PubMed PMID: 24920977.
26. Portnoy GA, Haskell SG, King MW, Maskin R, Gerber MR, Iverson KM. Accuracy and Acceptability of a Screening Tool for Identifying Intimate Partner Violence Perpetration among Women Veterans: A Pre-Implementation Evaluation. *Womens Health Issues*. 2018;28(5):439-45. Epub 2018/06/11. doi: 10.1016/j.whi.2018.04.003. PubMed PMID: 29885901.
27. O'Connor E, Rossom RC, Henninger M, Groom HC, Burda BU. Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*. 2016;315(4):388-406. Epub 2016/01/28. doi: 10.1001/jama.2015.18948. PubMed PMID: 26813212.
28. National Center for Immunization and Respiratory Diseases. Vaccines During and After Pregnancy: Centers for Disease Control and Prevention; [updated November 9, 2021]. Available from: <https://www.cdc.gov/vaccines/pregnancy/vacc-during-after.html>.
29. National Center for Immunization and Respiratory Diseases (NCIRD) DoVD. Vaccines for Family and Caregivers: Centers for Disease Control and Prevention; [updated November 9, 2021]. Available from: <https://www.cdc.gov/vaccines/pregnancy/family-caregivers.html#:~:text=Newborns%20do%20not%20yet%20have,preteens%2C%20teens%2C%20and%20adults>).
30. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. *MMWR Morb Mortal Wkly Rep*. 2013;62(7):131-5. Epub 2013/02/22. PubMed PMID: 23425962.
31. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2018;67(2):1-44. Epub 2018/04/28. doi: 10.15585/mmwr.rr6702a1. PubMed PMID: 29702631.
32. Englund J, Glezen WP, Piedra PA. Maternal immunization against viral disease. *Vaccine*. 1998;16(14-15):1456-63. Epub 1998/08/26. doi: 10.1016/s0264-410x(98)00108-x. PubMed PMID: 9711788.
33. National Center for Immunization and Respiratory Diseases (NCIRD). Maternal vaccines: Part of a healthy pregnancy: Centers for Disease Control and Prevention; 2016. Available from: <https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/important-maternal-vaccines.html>.
34. National Center for Immunization and Respiratory Diseases (NCIRD) DoVD. Covid-19 vaccines while pregnant or breastfeeding: Centers for Disease Control and Prevention; [updated October 20, 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html#anchor_1628692641537.
35. Centers for Disease Control and Prevention. Pregnant and Recently Pregnant People at Increased Risk for Severe Illness from COVID-19 [updated October 25, 2022]. Available

from:

<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnant-people.html>.

36. Smego RA, Jr., Asperilla MO. Use of acyclovir for varicella pneumonia during pregnancy. *Obstet Gynecol.* 1991;78(6):1112-6. Epub 1991/12/11. PubMed PMID: 1945218.
37. Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. *N Engl J Med.* 1986;314(24):1542-6. Epub 1986/06/12. doi: 10.1056/nejm198606123142403. PubMed PMID: 3012334.
38. Brunell PA. Fetal and neonatal varicella-zoster infections. *Semin Perinatol.* 1983;7(1):47-56. Epub 1983/01/01. PubMed PMID: 6682573.
39. Smith WJ, Jackson LA, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. *Obstet Gynecol.* 1998;92(4 Pt 1):535-45. Epub 1998/10/09. doi: 10.1016/s0029-7844(98)00221-x. PubMed PMID: 9764625.
40. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2007;56(Rr-4):1-40. Epub 2007/06/23. PubMed PMID: 17585291.
41. National Center for Immunization and Respiratory Diseases (NCIRD). Varicella Vaccine Recommendations: Centers for Disease Control and Prevention; [updated April 28, 2021]. Available from: <https://www.cdc.gov/vaccines/vpd/varicella/hcp/recommendations.html>.
42. McElhaney RD, Jr., Ringer M, DeHart DJ, Vasilenko P. Rubella immunity in a cohort of pregnant women. *Infect Control Hosp Epidemiol.* 1999;20(1):64-6. Epub 1999/02/02. doi: 10.1086/501558. PubMed PMID: 9927272.
43. Chang TW, DesRosiers S, Weinstein L. Clinical and serologic studies of an outbreak of rubella in a vaccinated population. *N Engl J Med.* 1970;283(5):246-8. Epub 1970/07/30. doi: 10.1056/nejm197007302830507. PubMed PMID: 5424733.
44. Horstmann DM, Schluederberg A, Emmons JE, Evans BK, Randolph MF, Andiman WA. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. *Rev Infect Dis.* 1985;7 Suppl 1:S80-5. Epub 1985/03/01. doi: 10.1093/clinids/7.supplement_1.s80. PubMed PMID: 4001740.
45. National Center for Immunization and Respiratory Diseases (NCIRD). Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Know: Centers for Disease Control and Prevention; [updated January 26, 2021]. Available from: <https://www.cdc.gov/vaccines/vpd/mmr/public/index.html#:~:text=It%20is%20safe%20for%20breastfeeding,the%20vaccine%20through%20breast%20milk>.
46. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep.* 2019;68(32):698-702. Epub 2019/08/16. doi: 10.15585/mmwr.mm6832a3. PubMed PMID: 31415491.
47. Centers for Disease Control and Prevention. Research on medicines and pregnancy 2022 [updated September 20, 2022]. Available from: <https://www.cdc.gov/pregnancy/meds/treatingfortwo/research.html>.

48. Lynch MM, Amoozegar JB, McClure EM, Squiers LB, Broussard CS, Lind JN, et al. Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists. *Qual Health Res.* 2017;27(13):2071-80. Epub 2017/10/05. doi: 10.1177/1049732317732027. PubMed PMID: 28974142.
49. Kegel AH. Progressive resistance exercise in the functional restoration of the perineal muscles. *Am J Obstet Gynecol.* 1948;56(2):238-48. Epub 1948/08/01. doi: 10.1016/0002-9378(48)90266-x. PubMed PMID: 18877152.
50. Bø K, Sherburn M. Evaluation of female pelvic-floor muscle function and strength. *Phys Ther.* 2005;85(3):269-82. Epub 2005/03/01. PubMed PMID: 15733051.
51. Laycock J, Jerwood D. Pelvic Floor Muscle Assessment: The PERFECT Scheme. *Physiotherapy.* 2001;87(12):631-42. doi: 10.1016/S0031-9406(05)61108-X.
52. Wilson LC. The Prevalence of Military Sexual Trauma: A Meta-Analysis. *Trauma Violence Abuse.* 2018;19(5):584-97. Epub 2018/11/13. doi: 10.1177/1524838016683459. PubMed PMID: 30415636.
53. Gawron LM, Mohanty AF, Kaiser JE, Gundlapalli AV. Impact of Deployment on Reproductive Health in U.S. Active-Duty Servicewomen and Veterans. *Semin Reprod Med.* 2018;36(6):361-70. Epub 2019/04/20. doi: 10.1055/s-0039-1678749. PubMed PMID: 31003251.
54. Kilpatrick SJ PL-A, Macones GA, Watterberg KL. Guidelines for Perinatal Care: American Academy of Pediatrics; 2017.
55. Force UPST. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2017;317(16):1661-7. doi: 10.1001/jama.2017.3439.
56. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019. *MMWR Morb Mortal Wkly Rep.* 2022;71(17):585-91. Epub 2022/04/29. doi: 10.15585/mmwr.mm7117a1. PubMed PMID: 35482575.
57. Triunfo S, Lanzone A. Impact of maternal under nutrition on obstetric outcomes. *J Endocrinol Invest.* 2015;38(1):31-8. Epub 2014/09/10. doi: 10.1007/s40618-014-0168-4. PubMed PMID: 25194427.
58. Katon J, Mattocks K, Zephyrin L, Reiber G, Yano EM, Callegari L, et al. Gestational diabetes and hypertensive disorders of pregnancy among women veterans deployed in service of operations in Afghanistan and Iraq. *J Womens Health (Larchmt).* 2014;23(10):792-800. Epub 2014/08/05. doi: 10.1089/jwh.2013.4681. PubMed PMID: 25090022.
59. Division of Nutrition Physical Activity and Obesity. National Center for Chronic Disease Prevention and Health Promotion. Defining Adult Overweight & Obesity: Centers for Disease Control and Prevention; 2016 [updated June 3, 2022]. Available from: https://www.cdc.gov/obesity/basics/adult-defining.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Fadult%2Fdefining.html.

60. Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828. *Obstet Gynecol.* 2021;137(6):e177-e97. Epub 2021/05/21. doi: 10.1097/aog.0000000000004407. PubMed PMID: 34011892.
61. Moyer VA. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160(6):414-20. Epub 2014/01/16. doi: 10.7326/m13-2905. PubMed PMID: 24424622.
62. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 1998;47(Rr-3):1-29. Epub 1998/05/01. PubMed PMID: 9563847.
63. U.S. Preventive Services Task Force. Rh(D) Incompatibility: Screening 2004. Available from: <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/rh-d-incompatibility-screening>.
64. Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. *Obstet Gynecol.* 2020;135(2):e51-e72. Epub 2020/01/25. doi: 10.1097/aog.0000000000003668. PubMed PMID: 31977795.
65. Filkins L, Hauser JR, Robinson-Dunn B, Tibbetts R, Boyanton BL, Revell P. American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus. *J Clin Microbiol.* 2020;59(1). Epub 2020/10/30. doi: 10.1128/jcm.01230-20. PubMed PMID: 33115849.
66. Price D, Shaw E, Howard M, Zazulak J, Waters H, Kaczorowski J. Self-sampling for group B streptococcus in women 35 to 37 weeks pregnant is accurate and acceptable: a randomized cross-over trial. *J Obstet Gynaecol Can.* 2006;28(12):1083-8. Epub 2006/12/16. doi: 10.1016/s1701-2163(16)32337-4. PubMed PMID: 17169231.
67. Thorp JM, Jr., Jenkins T, Watson W. Utility of Leopold maneuvers in screening for malpresentation. *Obstet Gynecol.* 1991;78(3 Pt 1):394-6. Epub 1991/09/11. PubMed PMID: 1876372.
68. De Castro H, Ciobanu A, Formuso C, Akolekar R, Nicolaides KH. Value of routine ultrasound examination at 35-37 weeks' gestation in diagnosis of non-cephalic presentation. *Ultrasound Obstet Gynecol.* 2020;55(2):248-56. Epub 2019/11/02. doi: 10.1002/uog.21902. PubMed PMID: 31671470.
69. Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. *Obstet Gynecol.* 2014;123(3):693-711. Epub 2014/02/21. doi: 10.1097/01.AOG.0000444441.04111.1d. PubMed PMID: 24553167.
70. External Cephalic Version: ACOG Practice Bulletin, Number 221. *Obstet Gynecol.* 2020;135(5):e203-e12. Epub 2020/04/26. doi: 10.1097/aog.0000000000003837. PubMed PMID: 32332415.
71. ACOG Committee Opinion No. 736: Optimizing Postpartum Care. *Obstet Gynecol.* 2018;131(5):e140-e50. Epub 2018/04/24. doi: 10.1097/aog.0000000000002633. PubMed PMID: 29683911.
72. Division of Reproductive Health NCfCDPaHP. Summary of Classifications for Hormonal Contraceptive Methods and Intrauterine Devices: Centers for Disease Control and

- Prevention; [updated March 27, 2023]. Available from:
https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixk.html#mec_personal.
73. Vricella LK, Gawron LM, Louis JM. Society for Maternal-Fetal Medicine (SMFM) Consult Series #48: Immediate postpartum long-acting reversible contraception for women at high risk for medical complications. *Am J Obstet Gynecol*. 2019;220(5):B2-b12. Epub 2019/02/11. doi: 10.1016/j.ajog.2019.02.011. PubMed PMID: 30738885.
 74. Breastfeeding Challenges: ACOG Committee Opinion, Number 820. *Obstet Gynecol*. 2021;137(2):e42-e53. Epub 2021/01/23. doi: 10.1097/aog.0000000000004253. PubMed PMID: 33481531.
 75. Meek JY, Noble L. Policy Statement: Breastfeeding and the Use of Human Milk. *Pediatrics*. 2022;150(1). Epub 2022/08/04. doi: 10.1542/peds.2022-057988. PubMed PMID: 35921640.
 76. Odom EC, Li R, Scanlon KS, Perrine CG, Grummer-Strawn L. Reasons for earlier than desired cessation of breastfeeding. *Pediatrics*. 2013;131(3):e726-32. Epub 2013/02/20. doi: 10.1542/peds.2012-1295. PubMed PMID: 23420922.
 77. Mao CY, Narang S, Lopreiato J. Breastfeeding practices in military families: a 12-month prospective population-based study in the national capital region. *Mil Med*. 2012;177(2): 229-34. Epub 2012/03/01. doi: 10.7205/milmed-d-11-00181. PubMed PMID: 22360072.
 78. Committee Opinion No. 569: oral health care during pregnancy and through the lifespan. *Obstet Gynecol*. 2013;122(2 Pt 1):417-22. Epub 2013/08/24. doi: 10.1097/01.Aog.0000433007.16843.10. PubMed PMID: 23969828.
 79. Offenbacher S, Beck JD, Jared HL, Mauriello SM, Mendoza LC, Couper DJ, et al. Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. *Obstet Gynecol*. 2009;114(3):551-9. Epub 2009/08/25. doi: 10.1097/AOG.0b013e3181b1341f. PubMed PMID: 19701034.
 80. Polyzos NP, Polyzos IP, Zavos A, Valachis A, Mauri D, Papanikolaou EG, et al. Obstetric outcomes after treatment of periodontal disease during pregnancy: systematic review and meta-analysis. *Bmj*. 2010;341:c7017. Epub 2010/12/31. doi: 10.1136/bmj.c7017. PubMed PMID: 21190966.
 81. Oral Health Care During Pregnancy Expert Workgroup. Oral Health Care During Pregnancy: A National Consensus Statement Washington, DC: =; 2012. Available from: <https://www.mchoralhealth.org/PDFs/OralHealthPregnancyConsensus.pdf>.
 82. The use of dental radiographs: update and recommendations. *J Am Dent Assoc*. 2006;137(9):1304-12. Epub 2006/09/02. doi: 10.14219/jada.archive.2006.0393. PubMed PMID: 16946440.
 83. Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. *Jama*. 2006;295(15):1809-23. Epub 2006/04/20. doi: 10.1001/jama.295.15.1809. PubMed PMID: 16622143.
 84. White K, Teal SB, Potter JE. Contraception after delivery and short interpregnancy intervals among women in the United States. *Obstet Gynecol*. 2015;125(6):1471-7. Epub 2015/05/23. doi: 10.1097/aog.0000000000000841. PubMed PMID: 26000519.

85. Hamrick JE, Ahmed AE, Witkop CT, Manetz KE, Mancuso JD. Unintended pregnancy among U.S. military active duty servicemembers: Estimates for 2018 and trends since 2005. *Contraception*. 2023;119:109894. Epub 2022/10/16. doi: 10.1016/j.contraception.2022.09.132. PubMed PMID: 36243127.
86. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. *Jama*. 2018;320(19):2020-8. Epub 2018/11/13. doi: 10.1001/jama.2018.14854. PubMed PMID: 30418471.
87. Berghella V, Saccone G. Exercise in pregnancy! *Am J Obstet Gynecol*. 2017;216(4):335-7. Epub 2017/02/27. doi: 10.1016/j.ajog.2017.01.023. PubMed PMID: 28236414.
88. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of pediatric cancers: a meta-analysis. *Clin Pharmacol Ther*. 2007;81(5):685-91. Epub 2007/02/23. doi: 10.1038/sj.clpt.6100100. PubMed PMID: 17314929.
89. Bodnar LM, Tang G, Ness RB, Harger G, Roberts JM. Periconceptional multivitamin use reduces the risk of preeclampsia. *Am J Epidemiol*. 2006;164(5):470-7. Epub 2006/06/15. doi: 10.1093/aje/kwj218. PubMed PMID: 16772374.
90. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol*. 1999;150(7):675-82. Epub 1999/10/08. doi: 10.1093/oxfordjournals.aje.a010070. PubMed PMID: 10512421.
91. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. *Cochrane Database Syst Rev*. 2000(2):Cd001056. Epub 2000/05/05. doi: 10.1002/14651858.Cd001056. PubMed PMID: 10796229.
92. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev*. 2015;2015(12):Cd007950. Epub 2015/12/15. doi: 10.1002/14651858.CD007950.pub3. PubMed PMID: 26662928.
93. Ickovics JR, Kershaw TS, Westdahl C, Magriples U, Massey Z, Reynolds H, et al. Group prenatal care and perinatal outcomes: a randomized controlled trial. *Obstet Gynecol*. 2007;110(2 Pt 1):330-9. Epub 2007/08/02. doi: 10.1097/01.Aog.0000275284.24298.23. PubMed PMID: 17666608.
94. Baldwin KA. Comparison of selected outcomes of CenteringPregnancy versus traditional prenatal care. *J Midwifery Womens Health*. 2006;51(4):266-72. Epub 2006/07/04. doi: 10.1016/j.jmwh.2005.11.011. PubMed PMID: 16814221.
95. Carter EB, Temming LA, Akin J, Fowler S, Macones GA, Colditz GA, et al. Group Prenatal Care Compared With Traditional Prenatal Care: A Systematic Review and Meta-analysis. *Obstet Gynecol*. 2016;128(3):551-61. Epub 2016/08/09. doi: 10.1097/aog.0000000000001560. PubMed PMID: 27500348.
96. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. *J Clin Epidemiol*. 2013;66(7):726-35. Epub 2013/04/11. doi: 10.1016/j.jclinepi.2013.02.003. PubMed PMID: 23570745.

97. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol*. 2013;66(7):719-25. Epub 2013/01/15. doi: 10.1016/j.jclinepi.2012.03.013. PubMed PMID: 23312392.
98. Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. *J Am Acad Nurse Pract*. 2008;20(12):600-7. Epub 2009/01/06. doi: 10.1111/j.1745-7599.2008.00360.x. PubMed PMID: 19120591.
99. Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, et al. The impact of patient-centered care on outcomes. *J Fam Pract*. 2000;49(9):796-804. Epub 2000/10/14. PubMed PMID: 11032203.
100. National Learning Consortium. Shared Decision Making 2013. Available from: https://www.healthit.gov/sites/default/files/nlc_shared_decision_making_fact_sheet.pdf.
101. Institute of Medicine. *Crossing the Quality Chasm: A New Health System for the 21st Century*. Washington DC: National Academies Press, 2001.

Access to the full guideline and additional resources is available at: <https://www.healthquality.va.gov/>.

